JW To Progress Dendritic Cell Therapeutics After Fund Raising
This article was originally published in PharmAsia News
South Korea's JW Group is accelerating efforts to develop cancer immune cell therapies by raising a total of KRW50bn ($42.9m), with the funds to be used for its novel drug development arm JW CreaGene, which has a number of innovative dendritic cell-based candidates in the pipeline.
You may also be interested in...
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.